{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:04:26Z","timestamp":1788908666683,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute for Health and Care Research Imperial College London Biomedical Research Centre"},{"name":"European Institute of Innovation and Technology"},{"name":"National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre"},{"name":"National Institute for Health and Care Research UK","award":["RP-2015-06-018"],"award-info":[{"award-number":["RP-2015-06-018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Sepsis gene-expression sub-phenotypes with prognostic and theranostic potential have been discovered. These have been identified retrospectively and have not been translated to methods that could be deployed at the bedside. We aimed to identify subgroups of septic patients at high-risk of poor outcome, using a rapid, multiplex RNA-based test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Adults with sepsis, in the intensive care unit (ICU) were recruited from 17 sites in the United Kingdom, Sweden and France. Blood was collected at days 2\u20135 (S1), 6\u20138 (S2) and 13\u201315 (S3) after ICU admission and analyzed centrally. Patients were assigned into \u2018high\u2019 and \u2018low\u2019 risk groups using two models previously developed for the Immune-Profiling Panel prototype on the bioM\u00e9rieux FilmArray\u00ae system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>357 patients were recruited (March 2021\u2013November 2022). 69% were male with a median age of 67 years, APACHE II score of 21 and a 30% 90-day mortality rate. The proportions of high-risk patients decreased over the three sampling times (model 1: 53%, 40%, 15% and model 2: 81%, 74%, 37%). In model 1, 90-day mortality was higher in a high-risk group at each time (S1: 35% vs 24%, <jats:italic>p<\/jats:italic>\u2009=\u20090.04; S2: 43% vs 20%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001; S3: 52% vs 24%, <jats:italic>p<\/jats:italic>\u2009=\u20090.007). In model 2, mortality was only significantly different at the second sampling time (S1: 30% vs 27%, <jats:italic>p<\/jats:italic>\u2009=\u20090.77; S2: 34% vs 14%, <jats:italic>p<\/jats:italic>\u2009=\u20090.002; S3: 35% vs 23%, <jats:italic>p<\/jats:italic>\u2009=\u20090.13).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Gene-expression diagnostics can identify patients with sepsis at high-risk of poor outcomes and could be used to identify patients for precision medicine trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration<\/jats:title>\n            <jats:p>ISRCTN11364482 Registered 24th September 2020.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13054-025-05319-5","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:07:58Z","timestamp":1741018078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An international observational study validating gene-expression sepsis immune subgroups"],"prefix":"10.1186","volume":"29","clinical-trial-number":[{"clinical-trial-number":"isrctn11364482","registry":"10.18810\/isrctn"}],"author":[{"given":"David B.","family":"Antcliffe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Peronnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"P\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Str\u00e5lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brealey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Blein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cleaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cronhjort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Voiriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Fleurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lannsj\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Lukaszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"M\u00e5rtensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e0i","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"De Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Damien","family":"Ricard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mervyn","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Terraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Timsit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Unge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Vieillard-Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka Rubenson","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Llitjos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"4","key":"5319_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","volume":"20","author":"JC Marshall","year":"2014","unstructured":"Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med. 2014;20(4):195\u2013203.","journal-title":"Trends Mol Med"},{"issue":"10219","key":"5319_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200\u201311.","journal-title":"Lancet"},{"issue":"9","key":"5319_CR3","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00134-018-5175-z","volume":"44","author":"CM Coopersmith","year":"2018","unstructured":"Coopersmith CM, De Backer D, Deutschman CS, Ferrer R, Lat I, Machado FR, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med. 2018;44(9):1400\u201326.","journal-title":"Intensive Care Med"},{"issue":"10","key":"5319_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1164\/rccm.202311-2086SO","volume":"2","author":"AC Gordon","year":"2024","unstructured":"Gordon AC, Alipanah-Lechner N, Bos LD, Dianti J, Diaz JV, Finfer S, et al. From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in ICU. Am J Respir Crit Care Med. 2024;2(10):155\u201366.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"5319_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1164\/rccm.201608-1685OC","volume":"196","author":"KL Burnham","year":"2017","unstructured":"Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC, Hutton P, et al. Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med. 2017;196(3):328\u201339.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"5319_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","volume":"4","author":"EE Davenport","year":"2016","unstructured":"Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016;4(4):259\u201371.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"5319_CR7","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2213-2600(17)30294-1","volume":"5","author":"BP Scicluna","year":"2017","unstructured":"Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med. 2017;5(10):816\u201326.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"5319_CR8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","volume":"199","author":"DB Antcliffe","year":"2019","unstructured":"Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic signatures in sepsis and a differential response to steroids from the VANISH randomized trial. Am J Respir Crit Care Med. 2019;199(8):980\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"5319_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1164\/rccm.201410-1864OC","volume":"191","author":"HR Wong","year":"2015","unstructured":"Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015;191(3):309\u201315.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"5319_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/CCM.0000000000005270","volume":"50","author":"F Venet","year":"2022","unstructured":"Venet F, Textoris J, Blein S, Rol ML, Bodinier M, Canard B, et al. Immune profiling demonstrates a common immune signature of delayed acquired immunodeficiency in patients with various etiologies of severe injury. Crit Care Med. 2022;50(4):565\u201375.","journal-title":"Crit Care Med"},{"issue":"Suppl 2","key":"5319_CR11","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1093\/infdis\/jiaa248","volume":"222","author":"DM Tawfik","year":"2020","unstructured":"Tawfik DM, Vachot L, Bocquet A, Venet F, Rimmel\u00e9 T, Monneret G, et al. Immune profiling panel: a proof-of-concept study of a new multiplex molecular tool to assess the immune status of critically ill patients. J Infect Dis. 2020;222(Suppl 2):S84.","journal-title":"J Infect Dis"},{"issue":"6","key":"5319_CR12","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/CCM.0000000000005832","volume":"51","author":"E Peronnet","year":"2023","unstructured":"Peronnet E, Blein S, Venet F, Cerrato E, Fleurie A, Llitjos JF, et al. Immune profiling panel gene set identifies critically ill patients with low monocyte human leukocyte antigen-DR expression: preliminary results from the reanimation low immune status marker (REALISM) Study. Crit Care Med. 2023;51(6):808.","journal-title":"Crit Care Med"},{"key":"5319_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13613-022-01051-3","volume":"12","author":"JA Tremblay","year":"2022","unstructured":"Tremblay JA, Peron F, Kreitmann L, Textoris J, Brengel-Pesce K, Lukaszewicz AC, et al. A stratification strategy to predict secondary infection in critical illness-induced immune dysfunction: the REALIST score. Ann Intensive Care. 2022;12:76.","journal-title":"Ann Intensive Care"},{"key":"5319_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13613-022-01010-y","volume":"12","author":"C De Roquetaillade","year":"2022","unstructured":"De Roquetaillade C, Dupuis C, Faivre V, Lukaszewicz AC, Brumpt C, Payen D. Monitoring of circulating monocyte HLA-DR expression in a large cohort of intensive care patients: relation with secondary infections. Ann Intensive Care. 2022;12:39.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"5319_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-62202-z","volume":"14","author":"E Peronnet","year":"2024","unstructured":"Peronnet E, Terraz G, Cerrato E, Imhoff K, Blein S, Brengel-Pesce K, et al. Use of immune profiling panel to assess the immune response of septic patients for prediction of worsening as a composite endpoint. Sci Rep. 2024;14(1):1\u201310.","journal-title":"Sci Rep"},{"key":"5319_CR16","doi-asserted-by":"crossref","unstructured":"Antcliffe DB, Peronnet E, P\u00e8ne F, Str\u00e5lin K, Brealey D, Cleaver R, et al. An International Multicenter Prospective Observational Clinical Study to Identify Gene-expression Sepsis Immune Subgroups and Their Associations With Clinical Outcomes. American Thoracic Society International Conference Meetings Abstracts. 2024;A4992\u2013A4992.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A4992"},{"key":"5319_CR17","unstructured":"Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals\u2014protocol version 5.3 [Internet]. [cited 2024 Feb 14]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/point-prevalence-survey-healthcare-associated-infections-and-antimicrobial-use-3"},{"issue":"6","key":"5319_CR18","doi-asserted-by":"publisher","first-page":"15734","DOI":"10.1136\/bmjopen-2016-015734","volume":"7","author":"ML Rol","year":"2017","unstructured":"Rol ML, Venet F, Rimmele T, Moucadel V, Cortez P, Quemeneur L, et al. The REAnimation low immune status markers (REALISM) project: a protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patients. BMJ Open. 2017;7(6):15734.","journal-title":"BMJ Open"},{"key":"5319_CR19","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2015."},{"issue":"6","key":"5319_CR20","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1213\/ane.0b013e318195e11d","volume":"108","author":"C Torgersen","year":"2009","unstructured":"Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, et al. Macroscopic postmortem findings in 235 surgical intensive care patients with sepsis. Anesth Analg. 2009;108(6):1841\u20137.","journal-title":"Anesth Analg"},{"issue":"1","key":"5319_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-66713-3","volume":"10","author":"C Goh","year":"2020","unstructured":"Goh C, Burnham KL, Ansari MA, de Cesare M, Golubchik T, Hutton P, et al. Epstein-Barr virus reactivation in sepsis due to community-acquired pneumonia is associated with increased morbidity and an immunosuppressed host transcriptomic endotype. Sci Rep. 2020;10(1):1\u20138.","journal-title":"Sci Rep"},{"issue":"50","key":"5319_CR22","doi-asserted-by":"publisher","first-page":"e2044","DOI":"10.1097\/MD.0000000000002044","volume":"94","author":"B Mathias","year":"2015","unstructured":"Mathias B, Szpila BE, Moore FA, Efron PA, Moldawer LL. A review of GM-CSF therapy in sepsis. Medicine. 2015;94(50):e2044.","journal-title":"Medicine"},{"issue":"10","key":"5319_CR23","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.4049\/jimmunol.1202062","volume":"189","author":"F Venet","year":"2012","unstructured":"Venet F, Foray AP, Villars-M\u00e9chin A, Malcus C, Poitevin-Later F, Lepape A, et al. IL-7 Restores lymphocyte functions in septic patients. J Immunol. 2012;189(10):5073\u201381.","journal-title":"J Immunol"},{"issue":"6","key":"5319_CR24","doi-asserted-by":"publisher","first-page":"e0199497","DOI":"10.1371\/journal.pone.0199497","volume":"13","author":"LK Thampy","year":"2018","unstructured":"Thampy LK, Remy KE, Walton AH, Hong Z, Liu K, Liu R, et al. Restoration of T Cell function in multi-drug resistant bacterial sepsis after interleukin-7, anti-PD-L1, and OX-40 administration. PLoS ONE. 2018;13(6):e0199497.","journal-title":"PLoS ONE"},{"key":"5319_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41591-022-01843-x","volume":"28","author":"DM Maslove","year":"2022","unstructured":"Maslove DM, Tang B, Shankar-Hari M, Lawler PR, Angus DC, Kenneth Baillie J, et al. Redefining critical illness. Nat Med. 2022;28:1141\u20138.","journal-title":"Nat Med"},{"key":"5319_CR26","unstructured":"Enne VI, Stirling S, Barber JA, High J, Russell C, Dhesi Z, et al. INHALE WP3, a multicentre, open-label, pragmatic randomised controlled trial assessing the impact of rapid, ICU-based, syndromic PCR, versus standard-of-care on antibiotic stewardship and clinical outcomes in hospital-acquired and ventilator associated pneumonia. Intensive Care Med. 2025;In press."},{"issue":"8","key":"5319_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"CS Calfee","year":"2014","unstructured":"Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA. Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611\u201320.","journal-title":"Lancet Respir Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05319-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05319-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05319-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:08:09Z","timestamp":1741018089000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-025-05319-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5319"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05319-5","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study gained ethical approval in each participating country: The Health and Care Research Wales research ethics committee (20\/LO\/1163) in the UK; the Comit\u00e9 de Protection des Personnes Ile de France X in France and the Swedish Ethical Review Authority in Sweden. Written informed consent was provided by participants or their legal representatives following local procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"ACG reports that outside of this work he has received consulting fees from AstraZeneca, Beckman Coulter, and VVB Bio, speaker fees from Fresenius Kabi and grant support from the NIHR HTA programme. DA reports grant support from the NIHR for work outside this project. FP reports that he has received speaker and consulting fees from Gilead outside of this work. JFT reported consulting and lecture fees for bioMerieux unrelated to the submitted work, consulting fees for Merck, Pfizer, Advanz pharma, Menarini, and lecture fees from Merck, Pfizer, Gilead, Mundipharma Qiagen unrelated to the article. JFT also declared research grants to his research group Merck, Pfizer. NP has served as an advisor or speaker for Moderna and AstraZeneca. EP, SB, AF and JFL are bioMerieux employees. EP and SB are co-inventors of patents related to the topic of the manuscript. GV has received research grants form bioM\u00e9rieux and SOS Oxyg\u00e8ne outside of this work, and support for attending meeting from SOS Oxyg\u00e8ne and Oxyvie. DB reports lecture fees for bioM\u00e9rieux unrelated to the submitted work and consulting for Synairgen and Abioinc. JDR has received speaker fees from Fisher&Paykel. TJ-F has received consulting\/speaker fees from MSD, Menarini, bioM\u00e9rieux, Qiagen, Shionogi, Mundipharma and Pfizer. A-CL reports support from bioM\u00e9rieux for work outside of this project. NDP reports grants, consulting and speaker fees from AstraZeneca and speaker fees from Moderna. MS reports grants from Gentin, consulting fees from Biotest, Matisse, deePull, Volition, Hemotune and Sanofi and speaker fees from bioM\u00e9rieux and AOP. The authors Dr Antcliffe and Prof Gordon are affiliated with the Department of Health and Social Care, Centre for Antimicrobial Optimization at Imperial College, London. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"98"}}